Dicerna Pharmaceuticals Inc (DRNA) 24.18 $DRNA
FDA Grants Orphan Drug Designation for DCR-PH1, Dicerna's Investigational Therapy for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
Business Wire - Thu Apr 23, 3:58PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to DCR-PH1, the company's therapeutic candidate for the treatment of primary hyperoxaluria type 1 (PH1). PH1 is a severe, rare, inherited disorder of the liver that often results in kidney failure, and for which there are no approved therapies.
DRNA: 24.18 (-0.25)
What's New in the Pharma Sector: Free Research on Asterias, Dicerna,OncoMed, Heron, and Providence Service Corporation
PR Newswire - Thu Apr 23, 7:20AM CDT
Editor Note: For more information about this release, please scroll to bottom.
PRSC: 49.35 (+0.02), HRTX: 14.18 (-0.06), DRNA: 24.18 (-0.25), OMED: 26.16 (+0.29), AST: 14.77 (+0.66)
BUYINS.NET: DRNA SqueezeTrigger Price is $19.63. There is $14,905,632 That Short Sellers Still Need To Cover.
M2 - Mon Apr 20, 1:03PM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring DURINA INC (NASDAQ RNA) in real time and just received an alert that DRNA is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 757400 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $19.63. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
DRNA: 24.18 (-0.25)
Dicerna Presents New B-catenin Data from Multiple Tumor Models at the 2015 RNA & Oligonucleotide Therapeutics Meeting at Cold Spring Harbor Laboratory
Business Wire - Fri Apr 10, 7:00AM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leader in the development of RNAi therapeutics, today announced promising new in vivo data for CTNNB1 DsiRNA in multiple patient-derived xenograft (PDX) and other models of diverse tumor types. CTNNB1 DsiRNA is an extended Dicer substrate short interfering RNA (DsiRNA-EX) therapeutic targeting B-catenin delivered using Dicerna's proprietary next generation EnCore(TM) lipid nanoparticle (LNP) technology. B-catenin, encoded by the CTNNB1 gene, is a well-studied oncology target that is validated by human genetic and functional evidence in a variety of cancers, including hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), and intrahepatic cholangiocarcinoma (IHCC).
DRNA: 24.18 (-0.25)
Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Business Wire - Tue Mar 31, 3:40PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based therapeutics targeting rare inherited diseases involving the liver and for cancers that are genetically defined, today announced that on March 31, 2015, the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 24,500 shares of common stock to four new employees, with all four grants having a grant date of March 31, 2015 (the "Q1 2015 Inducement Grants"
.
DRNA: 24.18 (-0.25)
Alpha- Antitrypsin Deficiency Therapeutics Pipeline Review, H1 2015
M2 - Thu Mar 26, 3:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l462rd/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Applied Genetic Technologies Corporation - Arrowhead Research Corporation - Carolus Therapeutics, Inc. - Cevec Pharmaceuticals GmbH - Dicerna Pharmaceuticals, Inc. - Grifols, S.A. - iBio, Inc. - Inhibrx - International Stem Cell Corporation - Intrexon Corporation - Kamada Ltd. - Polyphor Ltd. - Promethera Biosciences S.A. - Sangamo BioSciences, Inc. Drug Profiles - Alpha-1 Antitrypsin With rHuPH20 - alpha-1 proteinase inhibitor (human) second generation - ARC-AAT - CT-2009 - DC-AIM - Gene Therapy to Activate A1AT for Alpha 1-Antitrypsin Deficiency - Gene Therapy to Activate Alpha-1 Antitrypsin - HepaStem - POL-6014 - rAAV1-CB-hAAT - rAAV2-CB-hAAT - Recombinant A1PI - Recombinant Human Alpha-1 Antitrypsin - Recombinant Protein to Replace Alpha-1 Antitrypsin for Alpha Antitrypsin Deficiency - Recombinant Protein to Replace Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - RNAi Oligonucleotide for Alpha- Antitrypsin Deficiency - Stem Cell Therapy for Alpha-Antitrypsin Deficiency and Crigler-Najjar Syndrome For more information visit http://www.researchandmarkets.com/research/l462rd/alpha
DRNA: 24.18 (-0.25), ARWR: 7.28 (+0.05), SGMO: 14.70 (-0.84), XON: 44.10 (-0.91), KMDA: 4.71 (-0.01), IBIO: 1.07 (+0.07)
Dicerna Pharmaceuticals (DRNA) Crumbles: Stock Falls by 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 23, 7:46AM CDT
Dicerna Pharmaceuticals saw a big move last session, as the company’s shares fell by 6%. This stock, trading at a volatile range of $23.16–$26.94 in the past one-month time frame, showed a sharp decline on Friday
DRNA: 24.18 (-0.25), ACOR: 33.12 (-0.38)
'Mad Money' Lightning Round: I'm Staying Away From Five Below
at The Street - Thu Mar 19, 5:00AM CDT
Cramer isn't crazy about Dicerna Pharmaceuticals and Ziopharm Oncology but he likes Akamai and Lion Biotechnologies.
ZIOP: 10.81 (-0.39), AR: 42.56 (+0.26), DRNA: 24.18 (-0.25), AKAM: 75.74 (-0.53), LBIO: 12.34 (-0.08), FIVE: 36.04 (+0.10), ROST: 104.38 (-0.13)
Akamai Technologies Is A Terrific Connectivity Play - Cramer's Lightning Round (3/18/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Mar 19, 4:35AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, March 18. Bullish Calls: Akamai Technologies (NASDAQ: AKAM ): "This is a content delivery system, and I think it's terrific. We keep...
AR: 42.56 (+0.26), ZIOP: 10.81 (-0.39), HALO: 16.86 (-0.08), DRNA: 24.18 (-0.25), AKAM: 75.74 (-0.53), JUNO: 56.66 (-1.06), LBIO: 12.34 (-0.08), FIVE: 36.04 (+0.10), ROST: 104.38 (-0.13)
Jim Cramer's 'Mad Money' Recap: The Fed Does the Right Thing
at The Street - Wed Mar 18, 7:01PM CDT
The Federal Reserve is smarter than you think, Cramer says.
TSLA: 218.43 (-0.17), ZIOP: 10.81 (-0.39), AR: 42.56 (+0.26), DRNA: 24.18 (-0.25), AKAM: 75.74 (-0.53), FB: 81.53 (-0.88), WFC: 54.70 (-0.16), LBIO: 12.34 (-0.08), FIVE: 36.04 (+0.10), PLKI: 59.22 (+2.06), SBUX: 51.84 (+2.41), ESPR: 104.60 (-4.29), RCPT: 169.88 (-1.26), CRZO: 53.43 (-0.60), CRL: 77.40 (-0.49), MMP: 82.31 (+0.61), ROST: 104.38 (-0.13), REGN: 480.09 (+0.01)
Dicerna Pharmaceuticals' (DRNA) CEO Douglas Fambrough on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 12, 8:06PM CDT
DRNA: 24.18 (-0.25)
Dicerna Pharmaceuticals EPS in-line
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 3:34PM CDT
DRNA: 24.18 (-0.25)
Dicerna Announces Fourth Quarter and Full Year 2014 Financial and Operational Results
Business Wire - Thu Mar 12, 3:00PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics targeting rare inherited diseases involving the liver and genetically defined cancers, today announced financial and operational results for the quarter and full year ended December 31, 2014.
DRNA: 24.18 (-0.25)
5 Hated Earnings Stocks You Should Love
at The Street - Tue Mar 10, 8:30AM CDT
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.
FSYS: 11.03 (+0.11), SGMS: 12.80 (+0.20), DRNA: 24.18 (-0.25), KTOS: 5.63 (-0.05), JGW: 10.58 (-0.03)
Dicerna to Announce Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on March 12, 2015
Business Wire - Mon Mar 09, 3:18PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that the Company will release its fourth quarter and full year 2014 financial results after market close on Thursday, March 12, 2015.
DRNA: 24.18 (-0.25)
Dicerna to Present at the 2015 Leerink Global Healthcare Conference
Business Wire - Wed Feb 04, 3:15PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the 2015 Leerink Global Healthcare Conference. The presentation will take place at the Waldorf Astoria on Wednesday, February 11, 2015 at 1:00 p.m. ET in New York City.
DRNA: 24.18 (-0.25)
Dicerna Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Clinical Trial of DCR-MYC, an Investigational RNAi Therapeutic Targeting the MYC Oncogene, in Patients with Advanced Hepatocellular Carcinoma
Business Wire - Mon Feb 02, 6:30AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leader in the development of RNAi therapeutics, today announced that the first patient has been dosed in a global Phase 1b/2 clinical trial of DCR-MYC, an investigational Dicer substrate short interfering RNA (DsiRNA) therapeutic, in patients with advanced hepatocellular carcinoma (HCC). This new trial expands the development program for DCR-MYC, which is also being studied in a Phase 1 clinical trial in patients with solid tumors and hematological malignancies.
DRNA: 24.18 (-0.25)
Dicerna Announces Issuance of US Patent Providing Broad Coverage of DsiRNA-EX RNAi Payloads
Business Wire - Mon Jan 12, 6:46AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leader in the development of RNAi therapeutics, today announced that the United States Patent and Trademark Office (USPTO) issued to Dicerna Patent No. 8,927,705, "Single Stranded Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression," on January 6, 2015.
DRNA: 24.18 (-0.25)
Dicerna Pharmaceuticals Presents Positive Preclinical Data on its DsiRNA Therapeutics Targeting MYC and B-Catenin at AACR MYC: From Biology to Therapy Meeting
Business Wire - Mon Jan 12, 6:45AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leader in the development of RNAi therapeutics, today announced the presentation of new preclinical data on its Dicer substrate short interfering RNA (DsiRNA) therapeutics targeting MYC and B-catenin (CTNNB1) oncogenes in models of hepatocellular carcinoma (HCC) and colorectal cancer (CRC). The positive data, presented during a poster session on January 9 at MYC: From Biology to Therapy, a meeting of the American Association of Cancer Research (AACR) in La Jolla, Calif., provide additional insights into the parameters that impact the delivery and activity of DsiRNA therapeutics utilizing Dicerna's proprietary EnCore(TM) lipid nanoparticle (LNP) technology in HCC and CRC tumor models.
DRNA: 24.18 (-0.25)
Can the Rally in Dicerna Pharmaceuticals (DRNA) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 6:27AM CST
Can the Rally in Dicerna Pharmaceuticals (DRNA) Shares Continue?
DRNA: 24.18 (-0.25)
FDA Grants Orphan Drug Designation for DCR-PH1, Dicerna's Investigational Therapy for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
Business Wire - Thu Apr 23, 3:58PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to DCR-PH1, the company's therapeutic candidate for the treatment of primary hyperoxaluria type 1 (PH1). PH1 is a severe, rare, inherited disorder of the liver that often results in kidney failure, and for which there are no approved therapies. DRNA: 24.18 (-0.25)
What's New in the Pharma Sector: Free Research on Asterias, Dicerna,OncoMed, Heron, and Providence Service Corporation
PR Newswire - Thu Apr 23, 7:20AM CDT
Editor Note: For more information about this release, please scroll to bottom.
PRSC: 49.35 (+0.02), HRTX: 14.18 (-0.06), DRNA: 24.18 (-0.25), OMED: 26.16 (+0.29), AST: 14.77 (+0.66)
BUYINS.NET: DRNA SqueezeTrigger Price is $19.63. There is $14,905,632 That Short Sellers Still Need To Cover.
M2 - Mon Apr 20, 1:03PM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring DURINA INC (NASDAQ
RNA) in real time and just received an alert that DRNA is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 757400 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $19.63. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com . DRNA: 24.18 (-0.25)
Dicerna Presents New B-catenin Data from Multiple Tumor Models at the 2015 RNA & Oligonucleotide Therapeutics Meeting at Cold Spring Harbor Laboratory
Business Wire - Fri Apr 10, 7:00AM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leader in the development of RNAi therapeutics, today announced promising new in vivo data for CTNNB1 DsiRNA in multiple patient-derived xenograft (PDX) and other models of diverse tumor types. CTNNB1 DsiRNA is an extended Dicer substrate short interfering RNA (DsiRNA-EX) therapeutic targeting B-catenin delivered using Dicerna's proprietary next generation EnCore(TM) lipid nanoparticle (LNP) technology. B-catenin, encoded by the CTNNB1 gene, is a well-studied oncology target that is validated by human genetic and functional evidence in a variety of cancers, including hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), and intrahepatic cholangiocarcinoma (IHCC). DRNA: 24.18 (-0.25)
Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Business Wire - Tue Mar 31, 3:40PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based therapeutics targeting rare inherited diseases involving the liver and for cancers that are genetically defined, today announced that on March 31, 2015, the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 24,500 shares of common stock to four new employees, with all four grants having a grant date of March 31, 2015 (the "Q1 2015 Inducement Grants"
. DRNA: 24.18 (-0.25)
Alpha- Antitrypsin Deficiency Therapeutics Pipeline Review, H1 2015
M2 - Thu Mar 26, 3:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l462rd/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Applied Genetic Technologies Corporation - Arrowhead Research Corporation - Carolus Therapeutics, Inc. - Cevec Pharmaceuticals GmbH - Dicerna Pharmaceuticals, Inc. - Grifols, S.A. - iBio, Inc. - Inhibrx - International Stem Cell Corporation - Intrexon Corporation - Kamada Ltd. - Polyphor Ltd. - Promethera Biosciences S.A. - Sangamo BioSciences, Inc. Drug Profiles - Alpha-1 Antitrypsin With rHuPH20 - alpha-1 proteinase inhibitor (human) second generation - ARC-AAT - CT-2009 - DC-AIM - Gene Therapy to Activate A1AT for Alpha 1-Antitrypsin Deficiency - Gene Therapy to Activate Alpha-1 Antitrypsin - HepaStem - POL-6014 - rAAV1-CB-hAAT - rAAV2-CB-hAAT - Recombinant A1PI - Recombinant Human Alpha-1 Antitrypsin - Recombinant Protein to Replace Alpha-1 Antitrypsin for Alpha Antitrypsin Deficiency - Recombinant Protein to Replace Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - RNAi Oligonucleotide for Alpha- Antitrypsin Deficiency - Stem Cell Therapy for Alpha-Antitrypsin Deficiency and Crigler-Najjar Syndrome For more information visit http://www.researchandmarkets.com/research/l462rd/alpha
DRNA: 24.18 (-0.25), ARWR: 7.28 (+0.05), SGMO: 14.70 (-0.84), XON: 44.10 (-0.91), KMDA: 4.71 (-0.01), IBIO: 1.07 (+0.07)
Dicerna Pharmaceuticals (DRNA) Crumbles: Stock Falls by 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 23, 7:46AM CDT
Dicerna Pharmaceuticals saw a big move last session, as the company’s shares fell by 6%. This stock, trading at a volatile range of $23.16–$26.94 in the past one-month time frame, showed a sharp decline on Friday
DRNA: 24.18 (-0.25), ACOR: 33.12 (-0.38)
'Mad Money' Lightning Round: I'm Staying Away From Five Below
at The Street - Thu Mar 19, 5:00AM CDT
Cramer isn't crazy about Dicerna Pharmaceuticals and Ziopharm Oncology but he likes Akamai and Lion Biotechnologies.
ZIOP: 10.81 (-0.39), AR: 42.56 (+0.26), DRNA: 24.18 (-0.25), AKAM: 75.74 (-0.53), LBIO: 12.34 (-0.08), FIVE: 36.04 (+0.10), ROST: 104.38 (-0.13)
Akamai Technologies Is A Terrific Connectivity Play - Cramer's Lightning Round (3/18/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Mar 19, 4:35AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, March 18. Bullish Calls: Akamai Technologies (NASDAQ: AKAM ): "This is a content delivery system, and I think it's terrific. We keep...
AR: 42.56 (+0.26), ZIOP: 10.81 (-0.39), HALO: 16.86 (-0.08), DRNA: 24.18 (-0.25), AKAM: 75.74 (-0.53), JUNO: 56.66 (-1.06), LBIO: 12.34 (-0.08), FIVE: 36.04 (+0.10), ROST: 104.38 (-0.13)
Jim Cramer's 'Mad Money' Recap: The Fed Does the Right Thing
at The Street - Wed Mar 18, 7:01PM CDT
The Federal Reserve is smarter than you think, Cramer says.
TSLA: 218.43 (-0.17), ZIOP: 10.81 (-0.39), AR: 42.56 (+0.26), DRNA: 24.18 (-0.25), AKAM: 75.74 (-0.53), FB: 81.53 (-0.88), WFC: 54.70 (-0.16), LBIO: 12.34 (-0.08), FIVE: 36.04 (+0.10), PLKI: 59.22 (+2.06), SBUX: 51.84 (+2.41), ESPR: 104.60 (-4.29), RCPT: 169.88 (-1.26), CRZO: 53.43 (-0.60), CRL: 77.40 (-0.49), MMP: 82.31 (+0.61), ROST: 104.38 (-0.13), REGN: 480.09 (+0.01)
Dicerna Pharmaceuticals' (DRNA) CEO Douglas Fambrough on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 12, 8:06PM CDT
DRNA: 24.18 (-0.25)
Dicerna Pharmaceuticals EPS in-line
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 3:34PM CDT
DRNA: 24.18 (-0.25)
Dicerna Announces Fourth Quarter and Full Year 2014 Financial and Operational Results
Business Wire - Thu Mar 12, 3:00PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics targeting rare inherited diseases involving the liver and genetically defined cancers, today announced financial and operational results for the quarter and full year ended December 31, 2014.
DRNA: 24.18 (-0.25)
5 Hated Earnings Stocks You Should Love
at The Street - Tue Mar 10, 8:30AM CDT
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.
FSYS: 11.03 (+0.11), SGMS: 12.80 (+0.20), DRNA: 24.18 (-0.25), KTOS: 5.63 (-0.05), JGW: 10.58 (-0.03)
Dicerna to Announce Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on March 12, 2015
Business Wire - Mon Mar 09, 3:18PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that the Company will release its fourth quarter and full year 2014 financial results after market close on Thursday, March 12, 2015.
DRNA: 24.18 (-0.25)
Dicerna to Present at the 2015 Leerink Global Healthcare Conference
Business Wire - Wed Feb 04, 3:15PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the 2015 Leerink Global Healthcare Conference. The presentation will take place at the Waldorf Astoria on Wednesday, February 11, 2015 at 1:00 p.m. ET in New York City.
DRNA: 24.18 (-0.25)
Dicerna Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Clinical Trial of DCR-MYC, an Investigational RNAi Therapeutic Targeting the MYC Oncogene, in Patients with Advanced Hepatocellular Carcinoma
Business Wire - Mon Feb 02, 6:30AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leader in the development of RNAi therapeutics, today announced that the first patient has been dosed in a global Phase 1b/2 clinical trial of DCR-MYC, an investigational Dicer substrate short interfering RNA (DsiRNA) therapeutic, in patients with advanced hepatocellular carcinoma (HCC). This new trial expands the development program for DCR-MYC, which is also being studied in a Phase 1 clinical trial in patients with solid tumors and hematological malignancies. DRNA: 24.18 (-0.25)
Dicerna Announces Issuance of US Patent Providing Broad Coverage of DsiRNA-EX RNAi Payloads
Business Wire - Mon Jan 12, 6:46AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leader in the development of RNAi therapeutics, today announced that the United States Patent and Trademark Office (USPTO) issued to Dicerna Patent No. 8,927,705, "Single Stranded Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression," on January 6, 2015. DRNA: 24.18 (-0.25)
Dicerna Pharmaceuticals Presents Positive Preclinical Data on its DsiRNA Therapeutics Targeting MYC and B-Catenin at AACR MYC: From Biology to Therapy Meeting
Business Wire - Mon Jan 12, 6:45AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leader in the development of RNAi therapeutics, today announced the presentation of new preclinical data on its Dicer substrate short interfering RNA (DsiRNA) therapeutics targeting MYC and B-catenin (CTNNB1) oncogenes in models of hepatocellular carcinoma (HCC) and colorectal cancer (CRC). The positive data, presented during a poster session on January 9 at MYC: From Biology to Therapy, a meeting of the American Association of Cancer Research (AACR) in La Jolla, Calif., provide additional insights into the parameters that impact the delivery and activity of DsiRNA therapeutics utilizing Dicerna's proprietary EnCore(TM) lipid nanoparticle (LNP) technology in HCC and CRC tumor models. DRNA: 24.18 (-0.25)
Can the Rally in Dicerna Pharmaceuticals (DRNA) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 6:27AM CST
Can the Rally in Dicerna Pharmaceuticals (DRNA) Shares Continue?
DRNA: 24.18 (-0.25)
